The expiration of the Ozempic patent in populous countries like India and China paves the way for cheaper generic versions of GLP-1 medications, significantly impacting global health.
This week, the patent for semaglutide, the active ingredient in the injections Ozempic and Wegovy, is set to expire in India and China, the two most populous nations in the world. Following these countries, Brazil, South Africa, Turkey, and Mexico will also see the expiration, allowing for the production of much cheaper generic versions of GLP-1 medications. With these six countries representing 40% of the global population, the implications on public health worldwide are expected to be significant.
In contrast, the patent for Ozempic in the United States and Europe will not expire until the beginning of the next decade, as the patent holder has managed to extend the intellectual property rights in these regions through strategic commercial practices and prevailing local laws. This discrepancy highlights the difference in market access and affordability of critical medications between developed and developing countries.
In Argentina, the situation is unique; the drug has never been registered, and there is already a cheaper local version available. The current economic policies of the government may pave the way for Indian generics to enter the Argentine market as potential competitors. However, there are concerns that the momentum initially built by local advocates for affordable medications has dwindled, which could impact the success of these generics in Argentina's pharmaceutical landscape.
